Optimization of concomitant medication in Fabry cardiomyopathy

Acta Paediatr. 2007 Apr;96(455):81-3. doi: 10.1111/j.1651-2227.2007.00215.x.

Abstract

We describe a male patient with Fabry disease and use this case study to illustrate the importance of a detailed cardiovascular evaluation and the role of supportive therapy in routine management of the disease. The major areas of discussion include the management of exertional chest pain, progressive heart failure and the diagnosis and treatment of atrial and ventricular arrhythmia.

Conclusion: In the era of enzyme replacement therapy, conventional pharmacological and device-based therapies remain central to the management of cardiovascular symptoms and the prevention of complications, such as arrhythmia and stroke.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Agents / therapeutic use*
  • Fabry Disease / complications*
  • Heart Diseases / drug therapy*
  • Heart Diseases / etiology*
  • Humans
  • Male
  • Middle Aged

Substances

  • Cardiovascular Agents